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Abstract
Esophageal sponge cytology is an endoscopy alternative well accepted by patients with
extensive data for accuracy in the context of adenocarcinoma. Few studies have
assessed its feasibility in asymptomatic community members, and fewer still in East
Africa, where esophageal squamous cell carcinoma (ESCC) rates are high. We aimed to
assess the feasibility of a capsule-based diagnosis of esophageal squamous dysplasia
(ESD), an ESCC precursor, which may benefit epidemiological and early detection
research. We collected Cytosponge collections in 102 asymptomatic adults from
Kilimanjaro, Tanzania. Uptake, acceptability and safety were assessed. Participants
scored acceptability immediately following the procedure and 7 days later on a scale of
0 (least) to 10 (most acceptable). Slides from paraffin-embedded cell clots were read by
two pathologists for ESD and other pathologies. All participants (52 men, 50 women,
aged 30-77) swallowed the device at first attempt, 100 (98%) of which gave slides of
adequate cellularity. Acceptability scores were 10 (53%), 9 (24%), 8 (21%), 7 (2%) and
6 (1%), with no differences by age, sex or time of asking. Cytological findings were
esophageal inflammation (4%), atypical squamous cells of uncertain significance (1%),
low-grade dysplasia (1%), gastritis (22%) and suspected intestinal metaplasia (6%).
Setting-specific logistical and ethical considerations of study implementation are dis-
cussed. We demonstrate the safety, acceptability and feasibility of Cytosponge sampling
in this setting, paving the way for innovative etiology and early-detection research.
Targeted sampling strategies and biomarker development will underpin the success of
such initiatives. The study protocol is registered on ClinicalTrials.gov (NCT04090554).
Abbreviations: ASCUS, atypical squamous cells of unknown significance; EAC, esophageal adenocarcinoma; EC, esophageal cancer; ESD, esophageal squamous dysplasia; ESCC, esophageal
squamous cell carcinoma; LSIL, low-grade squamous intraepithelial lesion; IARC, International Agency for Research on Cancer; NIMR, National Institute of Medical Ethics
.
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1 | INTRODUCTION
Esophageal cancer (EC) was the seventh commonest cancer world-
wide with the sixth highest number of cancer deaths in 2018.1 Esoph-
ageal squamous cell carcinoma (ESCC) accounted for ~84% of this
estimated burden,2 exhibiting high incidence in East Africa3 along an
apparent “corridor” spanning from Ethiopia in the north to the Eastern
Cape of South Africa. In Tanzania, there were an estimated 2500 new
EC cases and deaths in 2018. Despite documentation of this African
ESCC corridor as early as the 1960s,4 its etiology is not fully under-
stood. Poor prognosis of ESCC in East Africa necessitates etiological
and early detection research.
Esophageal squamous dysplasia (ESD) is an established precursor to
ESCC,5 with effective endoscopic therapies capable of definitive treat-
ment at a preclinical stage,6 and making ESD an early detection target.
Additionally, ESD etiology partially overlaps with ESCC etiology, and
studies of ESD determinants may inform ESCC etiology.7 Such studies
are possible in areas or population subgroups where ESCC incidence
rates and thus ESD population prevalence is high. In one of the few stud-
ies to investigate the prevalence of ESD in an East African community,
an endoscopy survey of asymptomatic over 20 year olds in Bomet,
Kenya, found that 15% had ESD (any grade),8 indicating that similarly
high prevalence may occur in other East African settings.
ESD is diagnosed by endoscopy with Lugol's iodine and morpho-
logical confirmation of biopsied lesions.9 Endoscopy is invasive and
costly, which has led to the search for affordable less-invasive alterna-
tives.10 A similar need for nonendoscopic diagnosis applies to
Barrett's esophagus, a precursor to esophageal adenocarcinoma
(EAC). The Cytosponge is one alternative developed for Barrett's by
the Fitzgerald Lab at the UK MRC Cancer Unit.11 This “pill-on-a-
string” is swallowed and dissolves to release a sponge, which, when
retrieved, harvests cells from the esophagus. The cells are processed
into a paraffin block to create a pseudobiopsy to ease pathological
analysis. Biomarkers have been developed for Barrett's esophagus,
including an immunohistochemical biomarker (TFF3) and atypia,12-14
p53 and copy number assays for risk stratification.15 This approach is
also needed for ESD, though data on the diagnostic accuracy using
the Cytosponge for ESD are limited. A study among an asymptomatic
Iranian population found 61% sensitivity for any grade (n = 18) and
100% sensitivity for high grade (n = 2) ESD.16
In the United Kingdom, the device has been shown to be safe and
acceptable to adult patients, with only three adverse events (two sponge
detachments and a minor bleed) out of 4422 procedures, a 92% swallow
success and higher acceptability than endoscopy without sedation.14,17
No data exist on the feasibility of using the Cytosponge within the Tan-
zanian healthcare and laboratory infrastructure, or its acceptability and
safety among asymptomatic adults locally.
The simplicity and inexpensiveness of the Cytosponge make it an
attractive tool for resource-limited settings with high ESCC incidence.
Recognizing this potential, we aimed to evaluate the feasibility of
Cytosponge collections in the community setting of Kilimanjaro by
assessing: (a) willingness to participate and device acceptability,
including the ability to swallow the device; (b) device safety;
(c) sample processing quality in the context of laboratory infrastruc-
ture; and (d) the sample prevalence of Cytosponge morphologically
detected ESD and esophageal pathologies, with post hoc gastric find-
ings also reported. We also summarize key logistical, ethical and clini-
cal considerations in the setup of this de novo field study.
2 | MATERIALS AND METHODS
2.1 | Study design
We conducted a feasibility study of administering the Cytosponge in
a target of 100 age- and sex-stratified asymptomatic community par-
ticipants and volunteers in Tanzania, and assessed device acceptability
immediately after sponge administration and 7 days later. The study
was conducted at the Kilimanjaro Clinical Research Institute (KCRI)
Majengo Unit, a clinical research unit in an urban suburb of Moshi, Kil-
imanjaro. This is within the catchment area of a completed ESCC
case-control study, part of the Esophageal Squamous Cell Carcinoma
African PrEvention research (ESCCAPE; http://esccape.iarc.fr) project.
Majengo was selected owing to the need for emergency access to
endoscopy in this pilot phase, for example, to remove the sponge
endoscopically in the event of a detachment or to treat variceal bleed-
ing given the high incidence of liver disease in this population. The site
was equipped with a backup generator to power refrigerators during
frequent power cuts. Private rooms for Cytosponge procedures and
interviews, and participant waiting areas were designated, and a full-
time study nurse (AD) and research assistant (TN) were employed.
What's new?
Endoscopy is often the standard method for diagnosing
esophageal squamous cell carcinoma (ESCC). However, in
resource-limited regions, lower-cost alternatives are urgently
needed, especially for early-detection screening programs.
Esophageal sponge cytology is one such alternative, but
would it be useful for large-scale screening? In this prelimi-
nary study, the authors tested this “pill-on-a-string”
approach in a region of Tanzania with high ESCC incidence.
They found that the method is acceptable, safe, and feasible
for screening asymptomatic community members in a high-
risk region. These results will aid in the design of novel
aetiology, biomarker, and early-detection research studies.
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2.2 | Participant recruitment
Cytosponge appointments were conducted from September to
December 2019. Inclusion criteria were adult (≥30 years) residents of
Kilimanjaro District, approached ad hoc, informed of the study and
invited to participate. Other participants volunteered for the study
having heard about it. As this was the first use of the Cytosponge in
Africa, the study was based on a small community sample but did not
employ population-based random sampling. The target age and sex
distribution were 1:1 male:female ratio within each age band, where
20% were 30 to 39 years; 20% 40 to 49 years; 30% 50 to 59 years
and 30% were 60 years and older. The following exclusion criteria
were employed: food/drink within previous 4 hours; pregnancy; dys-
phagia; self-reported history of oropharyngeal/esophageal/gastric
cancer; prior esophageal surgery; esophageal varices; stricture or
requiring esophageal dilation; self-reported liver cirrhosis; history of
hematemesis; recent use of anticoagulants; cardiac event within previ-
ous 6 months; unable to provide informed consent. Participants were
reimbursed 20 000 TSh (~$8.70 USD).
2.3 | Questionnaire data
Participants underwent an interviewer-administered questionnaire
before Cytosponge collection. Data were collected on age; sex; partic-
ipation motive; ethnicity; HIV status and therapy; residential location;
education level; religion; EC family history; EC history of friends/
neighbors/colleagues; alcohol consumption (ever/never), consumption
(ever/never) of strong alcohol (ie, >30% alcohol by volume [ABV]);
smoked tobacco use (ever/never) and smokeless tobacco use (ever/
never). Data were collected using REDCap tools hosted at the Interna-
tional Agency for Research on Cancer (IARC).
2.4 | Cytosponge procedure
One week of on-site training was delivered by a senior research nurse
(IDB) in the Cytosponge (Europlaz Technologies, UK) standard operat-
ing procedure (SOP). After inspection for defects, the capsule was
placed toward the back of the tongue while the string was held by the
participant. The capsule was swallowed with water and 5 minutes was
allowed for it to dissolve in the stomach. The string was used to
retrieve the sponge, which was placed into a pot of SurePath preser-
vative (Becton Dickinson). Samples were refrigerated at 4C to 6C
and transported weekly to the KCMC pathology laboratory.
2.5 | Cytosponge acceptability and safety
After the procedure, participants were shown a visual analogue
scale13 and asked to score the procedure from 0 to 10 (0 being
“completely unacceptable” and 10 being “completely acceptable”).
The closest Swahili translations were haikubaliki and inakubalika,
respectively. The number of attempts to swallow the capsule was
recorded. Adverse events were reported in accordance with Good
Clinical Practice (GCP) guidelines for clinical trials and independently
assessed for relatedness and severity. Participants were given emer-
gency contact details of an endoscopy nurse. Telephone calls were
made 7 days after appointments, during which acceptability scores
were requested again, and details and duration of any discomfort.
2.6 | Sample processing and cytopathology
examination
One week training in sample processing and cytopathology review
was delivered by a biomedical scientist (MB) and histopathologist
(MOD). Cytosponge samples were processed into formalin-fixed par-
affin embedded (FFPE) blocks by adapting an SOP.18 Agarose gel
(Sigma-Aldrich) was substituted for plasma-thrombin and stirred into
the centrifuged cell pellets to form a clot. Blocks were transported to
IARC where slides were prepared by cutting two serial sections from
each block and staining with hematoxylin and eosin (H&E). Slides were
scanned at 40× magnification and uploaded to the SlidePath Digital
Image Hub, where they were read independently by two pathologists
(MOD and BA-A). A consensus on nonconcordant reviews was
reached by joint review remotely.
2.7 | Statistical analysis
Comparisons of categorical variables between age groups (dichoto-
mized using the median age of 51 years as a cut point) and sex were
performed using the chi-squared test, or Fisher's exact test if cells
contained <10 observations. Statistical analysis was performed using
R version 3.6.1.
3 | RESULTS
3.1 | Participant recruitment and characteristics
Figure 1 summarizes participant recruitment. In total, 144 people
were engaged, 31 (21.5%) of whom were ineligible. Of the 31, exclu-
sions were made for one or more of pregnancy (n = 9, 29%), cardiac
events or related medication (n = 8, 25.8%), dysphagia (n = 7, 22.6%),
history of haematemesis (n = 5, 16.1%), peptic ulcer (n = 5, 16.1%),
possible history of oropharyngeal cancer (n = 5, 16.1%), liver cirrhosis
(n = 2, 6.5%) and prior esophageal surgery (n = 1, 3.2%). Of 113 eligible
individuals, 11 (9.7%) refused participation, giving 102 consenting par-
ticipants. Of the 11 (9.7%) refusals, with a suggestion of more in men
(8 refusals; 13%) than women (3 refusals; 6%), most (>80%) refused at
the initial invitation or did not turn up to the appointment. Only one
person (9.1%) refused after seeing the device.
Participant characteristics are presented in Table 1. Near equal
numbers of men and women were recruited, aged between 30 and
77 years old and a mean age of 50.6 ± 11.6. Most participants
(75/102; 74%) had at least primary education. Chagga was the most
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frequently reported ethnicity (60%), higher among women (37/50;
74%) than men (24/52; 46%), partly owing to a higher number of male
Muslim participants (15/52; 28.8% vs 8/50; 16%) who reported
“other” ethnicity. Christianity was the predominant religion (79/102;
78%). Alcohol consumption (ever) was reported by 31 of 52 (60%)
males and 28 of 50 (56%) females; and tobacco usage by 40% of
males and 2% of females. The self-reported HIV prevalence was 6.9%
(n = 7 known positives). A high reporting of family history of EC was
found among women (12/50; 24%) compared to men (3/52; 3.8%).
3.2 | Cytosponge acceptability
Acceptability outcomes are presented in Table 2. Among con-
senting participants, 82% gave checking their health status as their
motivation for participating. All participants swallowed the device
at first attempt. Immediate postprocedure acceptability scores are
plotted in Figure 2. Scores ranged between 6 and 10, with the
majority (52.9%) of participants scoring 10, followed by 9 (23.5%)
and 8 (20.6), giving a mean of 9.3. Follow-up contact 7-day
postprocedure was successful for 91 (89%) participants (Table 2).
On average, there was no difference between the immediate
acceptability score and that at follow-up (mean difference: +0.08,
95% CI: −0.20, +0.36); however, 20% (18/91) of participants
reduced their score by 1 or 2. Discomfort was reported by 21 (22%)
of those followed-up, 18 (86%) of whom reported a sore throat—an
anticipated side effect. Symptoms of discomfort persisted for more
than 2 days in 10 (47.6%) of those who experienced them, but were
not assessed beyond 7 days.
3.3 | Cytosponge safety
Out of 103 opened devices, one was defective upon inspection
(knotted suture) and not used. Out of 102 procedures, one adverse
event occurred. Shortly after sponge withdrawal, a 49-year-old
female vomited visible amounts of blood in water. The participant
underwent a precautionary endoscopy the following day. No
active bleeds were observed in the esophagus, but a gastric ulcer
was identified as the likely cause of the bleed. None of the study
participants contacted the study nurse due to new or concerning
symptoms during the 7 day follow-up period. A small number of
mild immediate side effects were reported, including six partici-
pants who vomited or regurgitated water and one episode of
coughing.
3.4 | Sample processing quality
Cytology slides were prepared for 102 participants, with an additional slide
from a separate FFPE block for three participants due to poor cell clots in
the initial block. These were prepared by reprocessing cells remaining in the
leftover sample. Of these 105 slides, four were excluded due to low
cellularity. Two of those excluded were from participants with a second
FFPE block, giving one readable slide for 100 of 102 participants.
3.5 | Cytological findings
The prevalence of cytological findings among 100 participants with a
readable slide is shown in Table 3. No significant findings were made
in the esophageal squamous cells of 91 (91%) participants. Significant
inflammation was found in the squamous cells of four (4%) partici-
pants: acute esophagitis (n = 2); eosinophilic esophagitis (n = 1) and
ulcer slough (n = 1). Atypical squamous cells of uncertain significance
(ASCUS) were found for one (1%) participant: a 49-year-old female.
Low-grade squamous intraepithelial lesion (LSIL)—low-grade ESD—
was found for one (1%) participant who was a 69-year-old female.
The presence of columnar cells was observed on the slides of 90% of
F IGURE 1 Study recruitment flow chart
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participants, an indication that the Cytosponge had deployed in the
stomach and sampled the full length of the esophagus. No significant
findings were made in the gastric columnar cells of 75 (75%) partici-
pants. Significant gastric inflammation was found for 22 (22%) partici-
pants: chronic (n = 9; 9%) and active chronic (n = 13; 13%) gastritis.
Intestinal metaplasia (IM) was found in six (6%) participants' cells,
three of them not accompanied by gastritis. Barrett's esophagus could
not be ruled out despite a low expected prevalence of this disease
locally.
3.6 | Participant follow-up
Participants with ASCUS or LSIL were invited to undergo
chromoendoscopy with confirmatory biopsy and morphological evalu-
ation. Both declined follow-up. Participants with significant inflamma-
tion in esophageal squamous cells are being invited to a consultation
with a local clinician to ascertain information on symptoms. Partici-
pants with either gastritis or IM are being invited to be tested for
Helicobacter pylori infection.
TABLE 1 Characteristics of the study participants overall and by sex
n (column %)
Males Females Total
All participants, n (row %) 52 (51) 50 (49) 102 (100)
Age group (years) 30 to 39 11 (21.2) 10 (20) 21 (20.6)
40 to 49 11 (21.2) 10 (20) 21 (20.6)
50 to 59 14 (26.9) 15 (30) 29 (28.4)
60 to 75 14 (26.9) 15 (30) 29 (28.4)
75+ 2 (3.8) 0 (0) 2 (2)
Range 30–77 30-71 30–77
Mean ± SD 50.5 ± 12.3 50.6 ± 10.9 50.6 ± 11.6
Ethnic group Chagga 24 (46.2) 37 (74) 61 (59.8)
Pare 3 (5.8) 1 (2) 4 (3.9)
Maasai 2 (3.8) 0 (0) 2 (2)
Other 23 (44.2) 12 (24) 35 (34.3)
Education Primary or below 34 (61.5) 41 (82) 75 (73.5)
Started or completed secondary 14 (26.9) 9 (10) 23 (22.5)
University/tertiary 4 (7.7) 0 (0) 4 (3.9)
Religion Christian Catholic 24 (46.2) 19 (38) 43 (42.2)
Christian Protestant/Anglican 12 (23.1) 20 (40) 32 (31.4)
Christian Evangelist 1 (1.9) 3 (6) 4 (3.9)
Muslim 15 (28.8) 8 (16) 23 (22.5)
Family history of ECa Yes 3 (3.8) 12 (24) 15 (14.7)
No 49 (94.2) 38 (76) 87 (85.3)
Know anyone with ECb Yes 11 (21.2) 17 (34) 28 (27.5)
No 41 (78.8) 33 (66) 74 (72.5)
Ever alcohol consumption Yes 31 (59.6) 28 (56) 59 (57.8)
No 21 (40.4) 22 (44) 43 (42.2)
Ever strong alcohol consumptionc Yes 10 (32.3) 2 (7.1) 12 (20.3)
No 21 (67.7) 26 (92.9) 47 (79.7)
Ever tobacco smoking Yes 18 (34.6) 0 (0) 18 (17.6)
No 34 (65.4) 50 (100) 84 (82.4)
Ever smokeless tobacco Yes 5 (9.6) 1 (2) 6 (5.9)
No 47 (90.4) 49 (98) 96 (94.1)
HIV statusd HIV-positive 1 (1.9) 6 (12) 7 (6.9)
HIV-negative 39 (75) 36 (72) 75 (73.5)
Unknown 12 (23.1) 8 (16) 20 (19.6)
aSelf-reported family history of esophageal cancer.
bSelf-reported history of esophageal cancer in acquaintances such as friends, neighbors and colleagues;
cDefined as >30% ABV.
dSelf-reported HIV status.
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4 | DISCUSSION
We successfully conducted a Cytosponge feasibility study in
Tanzania—the first use of any such device in Tanzania, and the first
use of the Cytosponge in Africa. The device was swallowed and a
sample was collected from all 102 participants, who reported
extremely high acceptability, and 100 of which were prepared into
slides of adequate cellularity. One adverse advent occurred—bleeding
which may have resulted from a gastric ulcer. The following cytologi-
cal findings were made: significant esophageal inflammation (4%),
ASCUS (1%), LSIL (1%), gastritis (22%) and intestinal metaplasia (6%),
three of which were not accompanied by gastritis. These findings
require follow-up but indicate the potential utility of the approach.
The study benefited from strong international collaboration and
intensive on-site training. This ensured a complete swallow with entry
of the device into the stomach in 90% participants and allowed sam-
ple collection and processing procedures to be minimally adapted with
no infrastructural modifications, yielding a high compliance of sample
quality for examination.
Few studies have employed capsule sponges in Africa. Prototypes
date back to the 1960s,19 but devices comparable in design to the
Cytosponge include a locally manufactured device used on >2000
inhabitants in South Africa.20,21 A low proportion of swallowing fail-
ures (<2%) and suboptimal cellularity (~3%) were reported.20,21 A later
study22 evaluated the Oesotest as a clinical triage in Nairobi, Kenya.
An unspecified number of patients with dysphagia were unable to
swallow, but the device was successful in 60 endoscopy referrals and
moderate to good agreement was found with endoscopy findings,
that is, two histologically confirmed ESCC cases were also detected
by the Oesotoest.22 Our 100% swallow success and high acceptability
in Tanzanian are similarly encouraging. A notable feature of previous
studies is sample preparation, whereby sponges were smeared onto
slides and spray-fixed, which gives a lower cell yield than FFPE clots.
We noted a variability of cellularity in our slides, but only ~2% were
suboptimal for evaluation.
Compared to studies using the Cytosponge device, our median
acceptability score of 10 (from 0 to 10) is higher than the 6 from a
pooled analysis of 2672 UK procedures,17 and our mean (9.3) higher
than 7.3 from 80 in the United States.23 Our swallow success rate
was also 100% compared to 91%17 and 93%,23 but patients suffered
from reflux disease and eosinophilic esophagitis in both studies,
respectively. The single bleeding event in our study is high compared
to 2 of 4422 in pooled UK data,14,17 but a gastric ulcer meant we


























Completely unacceptable Completely acceptable
Mean score = 9.3
F IGURE 2 Immediate post-
Cytosponge procedure acceptability
scores for all participants (n = 102)
TABLE 3 Cytological findings from 100 readable slides from 100
study participants
Cytological finding n (%)
Esophageal findings (squamous cells)
No significant cytological finding 91 (91)
Significant inflammationa 4 (4)
Atypical squamous cells of uncertain significance
(ASCUS)
1 (1)
Low-grade squamous intraepithelial lesion (LSIL)—low-
grade ESD
1 (1)
High-grade squamous intraepithelial lesion (HSIL)—
high-grade ESD
0 (0%)
Gastric findings (columnar cells)
No significant cytological finding 75 (75)
Significant inflammation—active chronic gastritis 13 (13)
Significant inflammation—chronic gastritis 9 (9)
Other findingsb
Intestinal metaplasia 6 (6)
Note: Readable slides were unavailable for two participants due to low
cellularity. One additional readable slide was available for one participant,
which agreed with the original and is not included in the table.
aIncluding acute esophagitis (n = 2); eosinophilic esophagitis (n = 1); ulcer
slough (n = 1).
bFor 3 of 6 intestinal metaplasia diagnoses, Barrett's esophagus remained
a possibility to be confirmed by pathology. These three cases are
accounted for in the prevalence of “No significant cytological finding” in
both esophageal and gastric findings.
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could not conclusively attribute bleeding to the procedure.
Cytosponges were swallowed by all 300 of 301 asymptomatic individ-
uals in Iran, with no complications.16 Our findings may be limited by
choice of study site—a research unit where participation rates are
boosted by awareness, engagement and trust. Such high acceptability
may not be received in rural communities, or elsewhere in East Africa.
Nevertheless, they provide a much-needed basis for ongoing
research.
Although we primarily aimed to assess feasibility, findings from
other East African ESCC hotspots suggested a higher prevalence of
squamous atypia/dysplasia. An endoscopy survey of 305 asymptom-
atic adults in Kenya found dysplasia in 15%,8 albeit with a more sensi-
tive screening modality. Despite less refined processing protocols, a
South African sponge cytology study reported higher prevalence of
atypia (4.8%-14%), dysplasia (1.4%-8%) and carcinoma (0%-2.8%) in
1000 asymptomatic individuals.20 Several factors likely contributed to
1. Planning and
recruitment
• Community health considerations -Population risk factors that could impact 
the safety of device administration and risks posed to participants and 
patients: 
• Identify additional setting-specific health status that needs to be considered 
for Cytosponge safety and follow-up implications.
• Examples include HIV; high H pylori; schistosomiasis and heavy alcohol 
consumption.
• Possible risks include transmission risks to healthcare workers; gastric ulcer 
related bleeding events; esophageal varices.
2. Recruitment 
and sampling
• Operational infrastructure considerations - Infrastructure needs for sample 
collection and potential emergency interventions: 
• Although the sponge is an endoscopy alternative at first, endoscopy must be 
available at all times. Close liaison with endoscopy is needed, suspend study 
if the endoscopy unit is down.
• Electricity supply/generator with no long duration outages.
3. Follow-up 
care
• Downstream expertise, logistical and infrastructure considerations -
Infrastructure needs for the follow-up of findings and patient care:
• Lugol’s chromendoscopy must be available or introduced for follow -up of 
atypical findings.
• Time between sponge collection, slide reading and re-contacting participants 
–ensure that permits for international transfers and any contracts are in 
place prior to study commencement.
• Training of onsite pathologist in slide review assisted by slide scanning if 
available.
• Setting’s ESD-treatment abilities nearby or upon referral.
• Costs of abnormal oesophageal findings including cancer–study payment of 
diagnostic investigations, immediate therapeutic recommendations, and of 
longer-term follow up.
• Costs of other abnormal findings.
Ethical 
considerations
• Overarching ethical considerations
• Remuneration–in poorer populations exaggerated study compensation can 
lead to undue inducement.
• If a high percentage of referred participants refuse endoscopy, is it ethical to 
conduct wide scale Cytosponge studies?
F IGURE 3 Situation-specific considerations of the Cytosponge administration in a new low-resource setting. Considerations 1 to 3 are
presented top to bottom along the cascade of planning, recruitment and follow-up care, followed by overarching ethical considerations
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our lower prevalence: (a) without p53 staining, the sensitivity of the
Cytosponge for low-grade ESD is only 39% to 80% based on Iranian
findings16; (b) our study was conducted in an urban suburb, whereas
more ESCC cases originate from rural villages in this setting; and
(c) healthy-participation effect—the sample was not a general popula-
tion random sample and includes volunteers. Therefore, if ESD is to
be used as an early detection target or surrogate epidemiological out-
come in this setting, targeted sampling of high-risk populations and
geographic locations will be needed, and a sensitive ESD biomarker.
Proliferation markers and those of carcinogen exposures may also
prove useful assays, as shown for PAHs.24 Conversely, the high preva-
lence of gastritis detected (22%) is consistent with expectations given
the local prevalence of H pylori infection.
The greatest findings and considerations made in the present
study derived from taking a procedure which to date has mostly been
administered in people and health facilities in high resource settings,
and administering it in a contrasting setting with different sociocul-
tural contexts and medical infrastructure. Some of the questions, con-
siderations and concerns that arose are provided in Figure 3 and may
help to frame discussions in future studies. Suggested decisions are
not provided as these would need to be made in context and by each
setting's team.
In conclusion, the feasibility of Cytosponge sampling was demon-
strated in a Tanzanian setting where endoscopy services are resource
limited. Further research is needed to define the test's accuracy in this
setting, which may lend support for risk stratification, targeted popu-
lation sampling and downstream bioassay selection to realize the
potential of this appropriate health technology for early detection and
etiological investigation of ESCC.
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